Moleculin Biotech, Inc. (MBRX) Free cash flow 2016–2025
Moleculin Biotech, Inc. (MBRX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$22.7MFY2025 · since FY2016: -$3.8M → -$22.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$22.7M | +4.8% |
| FY2024 | -$23.9M | -0.7% |
| FY2023 | -$23.7M | +14.4% |
| FY2022 | -$27.7M | -46.1% |
| FY2021 | -$19.0M | -4.5% |
| FY2020 | -$18.1M | -5.2% |
| FY2019 | -$17.3M | -36.7% |
| FY2018 | -$12.6M | -71.7% |
| FY2017 | -$7.4M | -94.2% |
| FY2016 | -$3.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More MBRX financial trends
MBRX RevenueMBRX Net incomeMBRX Net marginMBRX Gross profitMBRX Gross marginMBRX Operating incomeMBRX Operating marginMBRX Operating cash flowMBRX Capital expendituresMBRX Return on equityMBRX Stock buybacksMBRX Dividends paidMBRX Total assetsMBRX Total liabilitiesMBRX Shareholders’ equityMBRX overview →